Search

1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline

This compound belongs to the isoquinolines and derivatives. … This medication is known to target mitogen-activated protein kinase 10.

(1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid

This compound belongs to the indole-3-acetic acid derivatives. … These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole. (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is known to target interleukin-2.

Ramosetron

Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. … It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.

N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid

This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.

Alphaprodine

PPI-2458

This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases … PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets.

SNS-314

Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death.

(+)-Mefloquine

(+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to

Amedalin

It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.

MORF-057

MORF-057 is under investigation in clinical trial NCT06226883 (A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease).